EP2010174A4 - Modulation pharmacologique des effets positifs des modulateurs des récepteurs ampa sur l'expression de neurotrophines - Google Patents

Modulation pharmacologique des effets positifs des modulateurs des récepteurs ampa sur l'expression de neurotrophines

Info

Publication number
EP2010174A4
EP2010174A4 EP07760896A EP07760896A EP2010174A4 EP 2010174 A4 EP2010174 A4 EP 2010174A4 EP 07760896 A EP07760896 A EP 07760896A EP 07760896 A EP07760896 A EP 07760896A EP 2010174 A4 EP2010174 A4 EP 2010174A4
Authority
EP
European Patent Office
Prior art keywords
receptor modulator
ampa receptor
pharmacological modulation
positive ampa
modulator effects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07760896A
Other languages
German (de)
English (en)
Other versions
EP2010174A2 (fr
Inventor
Julie C Lauterborn
Christine M Gall
Gary Lynch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of EP2010174A2 publication Critical patent/EP2010174A2/fr
Publication of EP2010174A4 publication Critical patent/EP2010174A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP07760896A 2006-04-20 2007-04-19 Modulation pharmacologique des effets positifs des modulateurs des récepteurs ampa sur l'expression de neurotrophines Withdrawn EP2010174A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79396606P 2006-04-20 2006-04-20
PCT/US2007/066947 WO2007124348A2 (fr) 2006-04-20 2007-04-19 Modulation pharmacologique des effets positifs des modulateurs des récepteurs ampa sur l'expression de neurotrophines

Publications (2)

Publication Number Publication Date
EP2010174A2 EP2010174A2 (fr) 2009-01-07
EP2010174A4 true EP2010174A4 (fr) 2012-05-09

Family

ID=38625729

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07760896A Withdrawn EP2010174A4 (fr) 2006-04-20 2007-04-19 Modulation pharmacologique des effets positifs des modulateurs des récepteurs ampa sur l'expression de neurotrophines

Country Status (6)

Country Link
US (3) US20090192199A1 (fr)
EP (1) EP2010174A4 (fr)
JP (1) JP2009534415A (fr)
AU (1) AU2007240469B2 (fr)
CA (1) CA2649844C (fr)
WO (1) WO2007124348A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008060375A2 (fr) * 2006-10-06 2008-05-22 The Regents Of The University Of Californina Régulation positive de niveaux de bdnf pour atténuer un retard mental
US20090239888A1 (en) * 2008-02-12 2009-09-24 Wisconsin Alumni Research Foundation Methods for Inhibiting Amyloid Precursor Protein and Beta-Amyloid Production and Accumulation
EP2301318B1 (fr) * 2009-09-07 2011-11-16 CLAAS Agrosystems GmbH & Co. KG Système de commande pour véhicule agricole doté d'une remorque pour marchandises, véhicule agricole et procédé de commande de la remorque pour marchandises du véhicule agricole
WO2011109398A2 (fr) 2010-03-02 2011-09-09 President And Fellows Of Harvard College Procédés et compositions pour le traitement du syndrome d'angelman et des troubles du spectre autistique
US20110257186A1 (en) * 2010-04-15 2011-10-20 Staubli Ursula V Compositions and methods for treating visual disorders
CN102276576B (zh) * 2011-06-02 2013-08-14 西北工业大学 苯甲酰胺化合物及其制备方法
KR101439203B1 (ko) 2013-03-29 2014-09-12 한림대학교 산학협력단 Ｆｋ506 결합단백질 융합단백질과 피노밤을 포함하는 뇌 허혈손상 치료용 약제학적 조성물
US10300155B2 (en) 2015-12-31 2019-05-28 Washington University Alpha-synuclein ligands
WO2023164338A2 (fr) * 2022-02-23 2023-08-31 The Jonathan Hurt Living Trust Compositions et méthodes de traitement de dysfonctionnements sexuels

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005104836A2 (fr) * 2004-04-16 2005-11-10 Albert Einstein College Of Medicine Of Yeshiva University Modeles de drosophile pour des maladies affectant l'apprentissage et la memoire

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998011892A1 (fr) * 1996-09-17 1998-03-26 The Regents Of The University Of California Modulation positive du recepteur ampa permettant d'ameliorer l'expression des facteurs neurotrophiques dans le cerveau

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005104836A2 (fr) * 2004-04-16 2005-11-10 Albert Einstein College Of Medicine Of Yeshiva University Modeles de drosophile pour des maladies affectant l'apprentissage et la memoire

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
O'NEILL M J ET AL: "Neutrophic actions of the novel AMPA receptor potentiator, LY404187, in rodent models of Parkinson's disease", EUROPEAN JOURNAL OF PHARMACOLOGY, ELSEVIER SCIENCE, NL, vol. 486, no. 2, 20 February 2004 (2004-02-20), pages 163 - 174, XP008130555, ISSN: 0014-2999, [retrieved on 20040121], DOI: 10.1016/J.EJPHAR.2003.12.023 *

Also Published As

Publication number Publication date
AU2007240469B2 (en) 2011-01-20
EP2010174A2 (fr) 2009-01-07
WO2007124348A2 (fr) 2007-11-01
US20130123248A1 (en) 2013-05-16
WO2007124348A3 (fr) 2008-12-04
CA2649844C (fr) 2011-07-05
CA2649844A1 (fr) 2007-11-01
JP2009534415A (ja) 2009-09-24
AU2007240469A1 (en) 2007-11-01
US20090192199A1 (en) 2009-07-30
US20110306601A1 (en) 2011-12-15

Similar Documents

Publication Publication Date Title
EP2010174A4 (fr) Modulation pharmacologique des effets positifs des modulateurs des récepteurs ampa sur l'expression de neurotrophines
IL194556A0 (en) Diazepan derivatives modulators of chemokine receptors
ZA200805757B (en) Indole sulfonamide modulators of progesterone receptors
ZA200906307B (en) 8-oxy-quinoline derivatives as bradykinin B2 receptor modulators
HK1129108A1 (en) Indoles as 5-ht6 modulators 5-ht6
IL196448A0 (en) Benzofuro-and benzothienopyryimidine modulators of the histamine h4 receptor
AU2007325315A8 (en) Heterocyclic modulators of TGR5
HK1126222A1 (en) Modulators of toll-like receptor 7
PL2081937T3 (pl) Triazolopirydazynowe modulatory kinaz białkowych
IL197334A0 (en) Method of inhibition of respiratory depression using positive allosteric ampa receptor modulators
IL194814A0 (en) Mglur5 modulators i
IL198989A0 (en) Modulators of cb1 receptors
EP2312949A4 (fr) Modulateurs allostériques positifs du récepteur m1 n-hétérocyclique
SI2081937T1 (sl) Triazolopiridazinski modulatorji proteinskih kinaz
EP2005381A4 (fr) Modulateur à couche de sockets sécurisés géré par un consommateur
GB0701992D0 (en) Grehlin Receptor Modulators
HK1143325A1 (en) Thieno-and furo-pyrimidine modulators of the histamine h4 receptor h4
ZA200807237B (en) Modulators of muscarinic receptors
IL198402A0 (en) Allosteric modulators of the a1 adenosine receptor
EP2023938A4 (fr) MODULATION DE L'EXPRESSION DE ChREBP
HK1126767A1 (en) Pyridooxazepine progesteron receptor modulators
ZA200904663B (en) CB1 receptor modulators
IL201484A0 (en) New progesterone receptor modulators
HK1096405A1 (en) Progesterone receptor modulators
GB0403368D0 (en) EP2 receptor modulators

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081029

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

R17D Deferred search report published (corrected)

Effective date: 20081204

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 35/30 20060101ALI20081223BHEP

Ipc: A61K 38/00 20060101ALI20081223BHEP

Ipc: A61K 51/00 20060101AFI20081223BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20120405

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/28 20060101ALI20120330BHEP

Ipc: A61K 31/4439 20060101ALI20120330BHEP

Ipc: A61K 45/06 20060101ALI20120330BHEP

Ipc: A61K 35/30 20060101ALI20120330BHEP

Ipc: A61K 38/00 20060101ALI20120330BHEP

Ipc: A61K 51/00 20060101AFI20120330BHEP

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20121106